Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...
Business Wire

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; ...
kcra.com

Pfizer/BioNTech say new COVID-19 booster generates 'substantially higher' protection against omicron

Pfizer and BioNTech said Friday that the immune responses against omicron BA.4/BA.5 subvariants were "substantially higher" in people who got its new bivalent booster compared with people who received ...
Nasdaq

Pfizer/BioNTech Omicron shot shows immune response against BQ.1.1 subvariant

Nov 18 (Reuters) - Pfizer Inc PFE.N and its German partner BioNTech SE BNTX.O said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the ...